While GLP-1 receptor agonists are widely used clinically [19], their efficacy as early metabolic interventions—before severe obesity metabolic disease develops—particularly when combined with lifestyle-based therapies, is largely unexplored. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.